Meanwhile, the results of the study showed that for patients with advanced non-small cell lung cancer with strongly positive PD-L1 expression, undergoing a dual-immunity combination therapy was more effective than chemotherapy in terms of both survival benefit and toxicity. The gene discussed is CD274; the disease is non-small cell lung carcinoma.